23andMe is making its first foray into retail, teaming up with U.K. health and beauty company Superdrug to sell its genetic tests in the country.
Foundation Medicine revealed a C-suite shakeup and changes to its board of directors as it nears the finish line of its pending deal with Roche. Read more >>
HalioDx, a new company focused on cancer companion diagnostics, is kicking off operations after a management buyout at Qiagen's ($QGEN) Marseille subsidiary. Read more >>
POPULAR COMMENT THREADS
Quest Diagnostics is forming a joint venture with global CRO Quintiles to provide laboratory services for clinical trials, lending its research and diagnostic know-how to biopharma partners with precision medicine initiatives. Read more >>
Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.
Helomics is lending its tumor profiling technology and diagnostic expertise to a U.K. genomics initiative, teaming up with Big Pharma and researchers to uncover new biomarkers and develop advanced tests.
Myriad Genetics is expanding its companion diagnostics partnership with AstraZeneca, planning to use Myriad's BRACAnalysis test to see which metastatic pancreatic cancer patients respond to AstraZeneca's Lynparza (olaparib).
The diagnostics industry will play a significant role in the Obama administration's just-released national action plan to combat the rise of antibiotic-resistant bacteria, such as CRE, which was implicated in the recent death of at least two patients in Los Angeles and many illnesses nationwide.
GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.
From Our Sister Sites
X-Chem, PPD's in-house biotech company, struck a deal with pioneering startup Navitor Pharmaceuticals, outlicensing some early-stage compounds discovered with its proprietary technology.
Through a storm of M&A activity, Actavis CEO Brent Saunders has climbed his way up into the CEO's chair at one of pharma's top 10 drugmakers--and it's a climb for which he's been well rewarded.